Michael Allen Luther

Curia Global, Inc. engages in drug research and development, and manufacturing. It offers drug delivery, drug development, analytical services, API development and manufacturing, and drug product solutions. The company was founded by Thomas E. D'Ambra on June 19, 1991 and is headquartered in Albany, NY.

Transgenomic, Inc. is a global biotechnology company, which provides personalized medicine in the detection and treatment of cancer and inherited diseases through its proprietary molecular technologies and world-class clinical and research services. It operates through the following reportable segments: Laboratory Services and Genetic Assays and Platforms. The Laboratory Services segment is a combination of clinical laboratories and pharmacogenomic services business segments. The Clinical Laboratories segment specializes in genetic testing for cardiology, neurology, mitochondrial disorders and oncology. The Laboratory Services segment also provides pharmacogenomics research services supporting Phase II and Phase III clinical trials conducted by pharmaceutical companies and it employs a variety of genomic testing service technologies, including ICE COLD-PCR technology.The Genetic Assay and Platforms segment includes WAVE System product, which has broad applicability to genetic variation detection in both molecular genetic research and molecular diagnostics. This segment also manufactures and sells consumable products that can be used on multiple, independent platforms. These products include SURVEYOR Nuclease and a range of chromatography columns. Transgenomic was founded on March 6, 1997 and is headquartered in Omaha, NE.

Charles River Laboratories, Inc. provides research models and laboratory animal support services. It offers quality research models and support services to the biomedical community. The company was founded in 1947 and is headquartered in Wilmington, MA.

Precipio Diagnostics LLC operates as a cancer diagnostics reference laboratory. It offers its customers community oncologists and hospitals access to academic institutions and has combined academic-level excellence with the sales and marketing expertise, the proper operational processes and the necessary service level standards required to deliver proper support. The company was founded by Ilan Danieli in 2011 and is headquartered in New Haven, CT.

Merck Frosst Canada Ltd. is a Canadian pharmaceutical company that has been inventing medicines and vaccines for over 130 years. The company is based in Kirkland, Canada. The company's mission is to save and improve lives by bringing forward solutions for some of the world's most challenging diseases.

Located at the heart of the North Carolina Research Campus (NCRC), the David H. Murdock Research Institute (DHMRI) bridges the research gap between academics and industry by providing R&D solutions in a customer-focused, yet collaborative environment. The DHMRI catalyzes innovation at the public-private interface by driving and supporting R&D efforts with partners who are located both on and off campus. The institute leverages state-of-the-art research technologies and expertise with integrated approaches to provide robust solutions to the growing biotechnology research field. The NCRC is a visionary effort to bring together scientists from public and private sectors to focus on innovation in the areas of agriculture, nutrition and human health. The NCRC is the vision of David H. Murdock, Chairman of Dole Foods, and currently houses 8 university research groups as well as a number of public and private organizations and companies. Working together with the campus partners, the DHMRI, a 501(c)3 research institute, supports R&D efforts by bringing together campus wide expertise and advanced instrumentation to deliver high-quality solutions in an efficient and cost-effective manner. The mission of the DHMRI is to offer a customer-focused environment that allows researchers to advance discovery and development at the intersection of agriculture, nutrition and human health. By combining the expertise provided by the NCRC with the DHMRI expertise and on-site technologies of the DHMRI, the institute delivers creative multi-disciplinary solutions to the most complex problems.

Islet Sciences, Inc. is a biotechnology company, which engaged in the research, development, and commercialization of new medicines and technologies for the treatment of metabolic diseases. Its product portfolio included small molecule therapeutics, islet cell transplantation, and a molecular diagnostic to detect the onset of diabetes. The company was founded on September 14, 1994 and is headquartered in Yorba Linda, CA.